by Plus Therapeutics | May 28, 2024 | Uncategorized
#ICYMI: Replay the #Glioblastoma Patient Webinar from last week, hosted by Dr. Al Musella. The presentation included information about the ReSPECT-GBM clinical trial’s promising targeted radiotherapeutic working to treat Recurrent Glioblastoma and included a...
by Plus Therapeutics | May 20, 2024 | Uncategorized
🌟 Happy National Clinical Trials Day! 🌟 Today, we honor the incredible advancements made possible through clinical trials. These pivotal studies bring hope by paving the way for groundbreaking treatments and cures. At Plus Therapeutics, we are proud to be at the...
by Plus Therapeutics | May 17, 2024 | Uncategorized
Exciting News! Our partner, Head for the Cure Foundation has launched a new patient and caregiver resource, “Join Your Path to Hope!” JPH gives personalized guidance and resources for every step of your brain tumor journey within three different paths: medical,...
by Plus Therapeutics | May 15, 2024 | LM
“Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern...
by Plus Therapeutics | May 10, 2024 | Uncategorized
Thank you to everyone who stopped by our booth at the AANS annual meeting to learn more about our ReSPECT Recurrent Glioblastoma and Leptomeningeal Metastases clinical trials! If you missed us and would like more information, you can send us an email at...
Recent Comments